Thrilled to be heading to Chicago for #ENDO2026 where I’ll be presenting “MASLD Integrated Management: Lifestyle, Comorbidities, and Cardiovascular Risk” on June 15. Looking forward to discussing MASLD, obesity, and cardiometabolic risk with colleagues from around the world.

And history has been made. The World Health Assembly resolution on steatotic liver disease passed. A huge thanks to WHO Member States, the Global Think-tank on Steatotic Liver Disease and all our partners and supporters linkedin.com/posts/global-th… #ActOnNCDs #SLDthinktank

📢Special Topic: Heart–Liver Integrated Management in Metabolic Disorders Exploring mechanisms, diagnostics, and treatments at the intersection of cardiovascular and liver disease in metabolic dysfunction. Submit by 31 Aug 2026 oaepublish.com/specials/mtod… #Metabolism #CardioHepatic

Inflammation as a therapeutic target in obesity-related disease The purinergic P2X7 receptor drives inflammasome activation and meta-inflammation, linking obesity with cardiovascular, kidney, and liver complications oaepublish.com/articles/mtod… #Obesity #Inflammation #CardioMetabolic

The UPF industry and those they pay frequently claim that criticising harmful food generates shame and stigma. What this series makes unequivocally clear is that the true source of shame/stigma around diet related disease is a food environment that forces so many people to eat harmful food. If you are living with diet related disease just remember - it’s not you, it’s the food

ALD and MetALD are driving a growing global burden of chronic liver disease, and the way we approach care is changing fast. At #EASLCongress 2026, this forward thinking session will offer a powerful preview of what the next generation of care could look like. From biomarker led risk stratification and multi omic profiling, to targeted pharmacological, nutritional and behavioural strategies, discover how precision medicine is reshaping the full disease continuum. The session will also highlight the rise of digital hepatology and mobile health tools, showing how scalable technologies can improve adherence, widen access and help reduce disparities. If you are working in hepatology, metabolic health or digital innovation, this is one to add to your agenda! 👉Register now and secure your place. easlcongress.eu/2026-registr… @DebbieShawcros1 @analleo

People living with obesity describe mental health as both a driver and consequence of weight, with trauma, stigma and “not fitting in” shaping daily life; this study argues for integrated psychological support as core obesity care, not an optional add‑on. nature.com/articles/s41366-0…

Impact of Semaglutide 2.4 mg on body composition and function: The SEMALEAN study shows 13% weight loss at 12 months with preserved lean mass, improved grip strength, and reduced sarcopenic obesity. Functional and metabolic health improved alongside fat loss. dom-pubs.onlinelibrary.wiley…

“Diet” foods aren’t always your friend when it comes to weight loss. Ultra-processed products like gluten-free snacks, fake meats, vegan cheeses, and protein bars can pack excess calories, sugars, and unhealthy fats - often undermining goals. Read my full comments on @Medscape: medscape.com/viewarticle/whe…

Adding @MyLife365_Me the FREE #liver #health app in 40 countries enables those who want to get tips and tricks that are #liver focused #MASLD #MASH #fattyliver

(3/3) Read our press release for full details: prnewswire.com/apac/news-rel… #FibroScanVCTE #MASH #ClinicalTrials #DrugDevelopment #LiverHealthMatters

(2/3) This milestone opens a path for FibroScan® to ultimately replace liver biopsy for patient enrollment and treatment response assessment in MASH drug development—making participation in clinical trials less burdensome and more accessible for people living with MASH.

(1/3) ✨Exciting news in liver health: the FDA has accepted Echosens’ Letter of Intent to qualify LSM by VCTE (FibroScan®) as the first non-invasive surrogate endpoint in MASH clinical trials.

🧬 Study shows MASLD shares key genes & pathways with diabetes, obesity, and lipids—offering new drug targets. 🔗 oaepublish.com/articles/mtod… #MASLD #Genetics #DrugDiscovery #LiverResearch

The EASL Studio is back! Tune in this Wednesday 18:00 CEST as the faculty explore the relevance of alkaline phosphatase response, non-invasive fibrosis assessment, and composite scores like GLOBE and UK-PBC. Read more: easl.eu/easl-studio-episode/… @MCarbone_80 @FrancqueSven #LiverTwitter #LiverX

🔥 Beyond the liver: Metabolic and sex-specific factors may hold the key to personalized MASLD treatments. Time to rethink one-size-fits-all care! 🔗 oaepublish.com/articles/mtod… #MASLD #MetabolicHealth #PrecisionMedicine #LiverResearch

The opportunity to translate the numbers seen on gaining a #Fibroscan and the discussion these initiate can be and are often life changing for many individuals Seeing the empowerment of an individual to address their health is a privilege and a rewarding experience

(4/5) “The numbers are eye-opening for almost every patient, and they’re powerful benchmarks I can use later to navigate progress and keep them motivated.”

Very encouraging and if this is you then track #lifestyle #diet #drink and #physicalactivity via @MyLife365_Me FREE #liverhealth app and add your #fibroscan make the change, track the change and see the change 👍🏻

This is great news and @MyLife365_Me the liver app is a available in Ireland so people who have a #fibroscan can download the app, log their scan and track lifestyle and changes they make if it needs improvement or just keeping it #healthy @TawazunH #liverhealth